Abstract Targeted Protein Modification (TPM) is an umbrella term encompassing numerous
tools and approaches that use bifunctional agents to induce a desired modification over the …

Introduction Target protein degradation (TPD) provides a novel therapeutic modality, other
than inhibition, through the direct depletion of target proteins. Two primary human protein …

Focal adhesion kinase (FAK), also known as protein tyrosine kinase 2 (PTK2), is a
ubiquitously expressed non-receptor tyrosine kinase, that plays a pivotal role in integrin …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Diverse drug design strategies viz. molecular hybridization, substituent installation, scaffold
hopping, isosteric replacement, high-throughput screening, induction and separation of …

Proteolysis targeting chimera (PROTAC) presents a powerful strategy for targeted protein
degradation (TPD). The heterobifunctional PROTAC molecule consists of an E3 ligase …

Combination of different molecular target inhibitors is an available method to improve the
therapeutic effect on tumors. Herein, to achieve both tumor cell targeting and ALK …

Cancer treatments with targeted therapy have gained immense interest due to their low
levels of toxicity and high selectivity. Proteolysis-Targeting Chimeras (PROTACs) have …

PROTAC is a rapidly developing engineering technology for targeted protein degradation
using the ubiquitin–proteasome system, which has promising applications for inflammatory …

Proteolysis targeting chimeras (PROTAC) are an emerging precision medicine strategy,
which targets key proteins for proteolytic degradation to ultimately induce cancer cell killing …